Lymphoid malignancies: Another face to the Janus kinases.

Abstract excerpt

Considerable attention has focused on the gain-of-function mutations in the Janus kinase-2 (JAK2) tyrosine kinase that are detectable in most patients with a myeloproliferative neoplasm. Activating mutations that target JAK2, as well as JAK1, or CRLF2 and IL7RA, two cytokine receptors with which the JAKs associate in lymphoid cells, have now been identified in a subset of pediatric patients diagnosed with acute...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to JAK1 gene
• Share to JAK2 gene
• Share to Janus Kinases